Sort
23,748 grants matching “melanoma”
HIV, HERV-K and Human Cancer
$524,710Marie-Louise Hammarskjold · University Of Virginia · R01 · FY2018 · CA
Investigating Regulatory Networks that Control Cell Proliferation and Apoptosis
$524,637Kurt Kohn · Division Of Basic Sciences - Nci · ZIA · FY2010 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma
$524,606Tobias Schatton · Brigham And Women'S Hospital · R01 · FY2021 · CA
Developing Selective EphA2 Inhibitors for the treatment of Cancer
$524,549Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2013 · CA
Developing Selective EphA2 Inhibitors for the treatment of Cancer
$524,549Nathanael Schiander Gray · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Molecular Epidemiology of Non-Melanoma Skin Cancer
$524,081Heather Nelson · University Of Minnesota · R01 · FY2011 · CA
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE TO MELANOMA
$523,876Michael T Lotze · University Of Pittsburgh At Pittsburgh · P01 · FY2009 · CA
Cell lineage and transcriptional analysis of the vertebrate neural plate border
$523,810Marianne Bronner-Fraser · California Institute Of Technology · R01 · FY2021 · DE
RNA-based Immunotherapy Targeting Antigens Unique to Brain Tumor Stem Cells
$523,631John H Sampson · Duke University · R01 · FY2010 · CA
Targeting Lymph Node Dependent Immune Tolerance in Cancer
$523,629Edgar G. Engleman · Stanford University · R01 · FY2022 · CA
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
$523,600Ellis G Levine · Roswell Park Cancer Institute Corp · U10 · FY2015 · CA
SKIN SELF EXAMINATION FOR EARLY DETECTION OF MELANOMA
$523,512Rhode Island Hospital (Providence, Ri) · R01 · FY2001 · CA
TCR signaling and cell cycle regulation in tumor-specific CD8 T cell dysfunction
$523,449Mary Philip · Vanderbilt University Medical Center · R37 · FY2024 · CA
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
$523,063Amnon Altman · La Jolla Institute For Immunology · R01 · FY2020 · CA
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
$523,063Michael Croft · La Jolla Institute For Immunology · R01 · FY2021 · CA
A Treg cell-intrinsic CTLA4-PKC-eta signaling pathway mediating contact-dependent suppression of tumor immunity: A novel target for cancer immunotherapy
$523,063Amnon Altman · La Jolla Institute For Immunology · R01 · FY2019 · CA
EARLY DETERMINANTS OF MELANOMA METASTASIS
$523,034New York University · · FY2021 · Defense Health Agency
Localized immunotherapy using alum-binding therapeutics
$522,925Darrell J Irvine · Massachusetts Institute Of Technology · R01 · FY2021 · EB
Clinical production of viral vectors for cancer gene therapy
$522,901Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2011 · CA
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN): A Phase II Clinica
$522,886Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2014 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
$522,831Arjun Raj · University Of Pennsylvania · R01 · FY2020 · CA
Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma
$522,753Jessie Villanueva · Wistar Institute · R01 · FY2022 · CA
(PQ #8) Biomarkers of efficacy and adverse events due to treatment with immune checkpoint inhibitors
$522,708Anton Wellstein · Georgetown University · R01 · FY2022 · CA
Mechanical regulation of the microenvironmental niche in skin tumorigenesis
$522,691Kandice Tanner · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Epidemiology of Cancer in a Cohort of Older Women
$522,496Aaron R Folsom · University Of Minnesota · R01 · FY2008 · CA